View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Nov. 26 (HealthDay News) -- Ranbaxy Laboratories Ltd., one of India's biggest pharmaceutical companies, has issued a voluntary recall for 41 batches of its generic version of atorvastatin calcium (Lipitor), with the full knowledge of the U.S. Food and Drug Administration.
The voluntary recall, which includes 10-, 20-, and 40-mg doses of atorvastatin, was prompted out of concern that select batches may contain small glass particles, less than 1 mm in size. The recall affects lots packaged in 90 and 500 count bottles and only affects certain select lot numbers. The recall does not affect 80-mg doses of atorvastatin.
A complete list of the recalled lot numbers, bottle sizes, and dosages can be found on Ranbaxy's U.S. website.
"Ranbaxy is proactively recalling the drug product lots out of an abundance of caution, and in keeping the safety of our customers in mind," per a statement on Ranbaxy's U.S. website.
List of Affected Batches
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top